LifeMD

LFMDP · NASDAQ

$21.30−$0.422 (−1.94%)TodayMarket closed · Oct 23, 4:15 PM ET

Prev close $21.72

Latest news

Press releaseSep 22, 5:01 PM ETGlobe Newswire
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
Press releaseAug 5, 7:45 PM ETGlobe Newswire
UPDATE - LifeMD Reports Second Quarter 2026 Results
Press releaseAug 5, 4:11 PM ETGlobe Newswire
LifeMD Reports Second Quarter 2026 Results
Press releaseJun 23, 8:00 AM ETGlobe Newswire
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
Press releaseJun 22, 8:00 AM ETGlobe Newswire
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
Press releaseJun 1, 8:05 AM ETGlobe Newswire
LifeMD Appoints Umesh Sripad as Chief Technology Officer
Press releaseMay 6, 4:05 PM ETGlobe Newswire
LifeMD Reports First Quarter 2026 Results
Press releaseApr 10, 8:15 AM ETGlobe Newswire
LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
Press releaseMar 31, 8:45 AM ETGlobe Newswire
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
Press releaseMar 24, 4:05 PM ETGlobe Newswire
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
Press releaseMar 16, 8:00 AM ETGlobe Newswire
LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
Press releaseMar 9, 4:05 PM ETGlobe Newswire
LifeMD Reports Fourth Quarter and Full Year 2025 Results
Press releaseJan 6, 8:30 AM ETGlobe Newswire
LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
Press releaseJan 5, 8:05 AM ETGlobe Newswire
LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill
Press releaseDec 26, 8:00 AM ETGlobe Newswire
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
Press releaseNov 24, 8:00 AM ETGlobe Newswire
LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026
Press releaseNov 17, 4:05 PM ETGlobe Newswire
LifeMD Reports Third Quarter 2025 Results
Press releaseNov 17, 8:00 AM ETGlobe Newswire
LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
Press releaseNov 5, 5:15 PM ETGlobe Newswire
LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
Press releaseNov 4, 9:15 AM ETGlobe Newswire
LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
Press releaseOct 22, 8:00 AM ETGlobe Newswire
LifeMD Names Dr. Tara Scott as Ambassador and Clinical Advisor for its Women's Health Program
Press releaseOct 1, 9:19 PM ETPRNewswire
LFMD Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP Before the Lead Plaintiff Deadline for Information About Leading the Securities Fraud Class Action Against LifeMD, Inc.
Press releaseSep 30, 8:00 AM ETGlobe Newswire
LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk
Press releaseSep 23, 4:05 PM ETGlobe Newswire
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
Press releaseSep 18, 8:00 AM ETGlobe Newswire
LifeMD Expands Pharmacy Services with Non-Sterile Compounding to Deliver Personalized, Cost-Efficient Therapies at Scale
Press releaseSep 3, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LifeMD, Inc. - LFMD
Press releaseAug 5, 4:05 PM ETGlobe Newswire
LifeMD Reports Second Quarter 2025 Results
Press releaseMay 6, 4:05 PM ETGlobe Newswire
LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance
Press releaseMar 10, 5:30 PM ETGlobe Newswire
LifeMD Reports Fourth Quarter 2024 Results
Press releaseNov 7, 4:05 PM ETGlobe Newswire
LifeMD Reports Third Quarter 2024 Results
Press releaseAug 7, 4:05 PM ETGlobe Newswire
LifeMD Reports Second Quarter 2024 Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

UPDATE - LifeMD Reports Second Quarter 2026 Results

LifeMD Reports Second Quarter 2026 Results

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

LifeMD Appoints Umesh Sripad as Chief Technology Officer

LifeMD Reports First Quarter 2026 Results

LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team

LifeMD Reports Fourth Quarter and Full Year 2025 Results

LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026

LifeMD Reports Third Quarter 2025 Results

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17

LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform

LifeMD Names Dr. Tara Scott as Ambassador and Clinical Advisor for its Women's Health Program

LFMD Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP Before the Lead Plaintiff Deadline for Information About Leading the Securities Fraud Class Action Against LifeMD, Inc.

LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD Expands Pharmacy Services with Non-Sterile Compounding to Deliver Personalized, Cost-Efficient Therapies at Scale

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LifeMD, Inc. - LFMD

LifeMD Reports Second Quarter 2025 Results

LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance

LifeMD Reports Fourth Quarter 2024 Results

LifeMD Reports Third Quarter 2024 Results

LifeMD Reports Second Quarter 2024 Results